Oncolytics Biotech Inc. filed a Form 8-K on November 20, 2026, disclosing the voting results from its 2026 Annual Meeting of Stockholders held on November 19, 2026, via an online virtual platform.

Key Highlights

  • Quorum reached: Stockholders representing 65,061,822 shares, or 49.61% of the 131,120,719 shares outstanding on the record date, were represented in person or by proxy.
  • Seven directors elected: All seven nominees were elected to serve until the 2027 annual meeting, with vote totals ranging from 86.45% to 90.39% in favor.
  • Auditor ratified: Baker Tilly US, LLP was ratified as independent registered public accounting firm for the year ending December 31, 2026, receiving 62,887,796 votes for and 1,694,520 against.
  • Executive compensation approved: The advisory vote on named executive officer compensation passed with 13,559,766 votes for and 9,777,095 against.
  • Frequency vote outcome: The Board's recommendation to hold the advisory executive compensation vote every three years did not receive a majority; stockholders favored annual votes (11,319,330 for one year vs. 9,781,900 for three years).
  • Board decision on frequency: Despite stockholder preference for annual votes, the Board determined it will continue to hold the advisory vote on executive compensation every three years.

Oncolytics Biotech 2026 Annual Meeting: Director Elections and Compensation Vote Details

According to the Form 8-K filed with the SEC by Oncolytics Biotech Inc. (NASDAQ:ONCY), the company's 2026 Annual Meeting of Stockholders was held on November 19, 2026, at 4:00 p.m. Eastern Time via a virtual online platform. The filing reports that 131,120,719 shares of common stock were outstanding on the record date, and that shares representing 65,061,822 votes, or 49.61%, were present in person or by proxy, constituting a quorum.

All seven director nominees were elected to hold office until the 2027 annual meeting. The filing shows Patricia S. Andrews received the highest share of votes at 90.39% (21,669,279 for, 2,304,481 withheld), while James T. Parsons received the lowest at 86.45% (20,724,255 for, 3,249,505 withheld). Each director election carried 41,088,062 broker non-votes. The ratification of Baker Tilly US, LLP as independent auditor for the fiscal year ending December 31, 2026, passed with 62,887,796 votes for, 1,694,520 against, and 479,506 abstentions, with no broker non-votes reported.

The filing discloses a notable outcome regarding the advisory frequency vote on executive compensation. While 11,319,330 votes favored holding the say-on-pay vote annually, 9,781,900 favored every three years, and 1,485,942 favored every two years, the filing states the Board's recommendation for a triennial vote "did not receive a majority of the votes cast." Despite this, the filing states the Board "has determined, and believe it to be in the best interest of the Company, to hold an advisory vote on executive compensation every three years, or until the Board otherwise determines that a different frequency for such advisory vote is in the best interest of the stockholders." The filing was signed by Kirk Look, Chief Financial Officer.

What Was Disclosed

Oncolytics Biotech filed voting results from its November 19, 2026 Annual Meeting, covering director elections, auditor ratification, executive compensation approval, and the frequency of future advisory compensation votes, with the Board electing to maintain a triennial schedule despite stockholder preference for annual votes.